Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$144.98M |
$4.57
+4.34%
|
|
ACTU
Actuate Therapeutics Inc
Actuate Therapeutics is a biotech company focused on oncology with a lead product elraglusib (a GSK-3β inhibitor).
|
$143.14M |
$6.89
+10.24%
|
|
CGEN
Compugen Ltd.
Company focus and programs are centered in oncology/immuno-oncology, qualifying under Biotech - Oncology.
|
$142.36M |
$1.59
|
|
SCLX
Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
|
$141.48M |
$20.23
-0.12%
|
|
ANIK
Anika Therapeutics, Inc.
Company develops and sells orthopedic devices including implants for cartilage repair and related regenerative solutions.
|
$141.01M |
$9.80
-1.80%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$140.94M |
$16.46
+2.84%
|
|
ACU
Acme United Corporation
SmartCompliance RFID First Aid kits indicate the company produces medical devices & biometrics-enabled safety products.
|
$140.76M |
$37.30
+0.48%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$140.02M |
$0.46
+10.84%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$139.29M |
$4.56
-2.77%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 is Relmada's lead oncology candidate targeting non-muscle invasive bladder cancer (NMIBC).
|
$139.07M |
$4.18
-1.88%
|
|
MRSN
Mersana Therapeutics, Inc.
Mersana is an oncology-focused biotechnology company with Emi-Le and XMT-2056 in clinical development.
|
$137.44M |
$27.63
+0.82%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$136.64M |
$1.34
+5.08%
|
|
MOLN
Molecular Partners AG
Core focus on oncology therapeutics built on the DARPin platform.
|
$136.10M |
N/A
|
|
ACNT
Ascent Industries Co.
Custom manufacturing / contract manufacturing services.
|
$133.96M |
$14.30
-1.99%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is Tonix's lead oral small-molecule drug for fibromyalgia (cyclobenzaprine HCl sublingual), a direct product the company develops and plans to bring to market.
|
$132.19M |
$15.06
+7.00%
|
|
BTMD
biote Corp.
Vertical pellet therapy and related implantable products can be categorized under Medical Devices & Biometrics.
|
$131.51M |
$2.67
+5.12%
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$131.12M |
$2.33
-0.21%
|
|
NKTX
Nkarta, Inc.
Nkarta is developing allogeneic CAR NK cell therapy (NKX019) for autoimmune diseases, directly fitting the Cell Therapy product category.
|
$129.97M |
$1.83
+1.38%
|
|
JYNT
The Joint Corp.
The Joint operates chiropractic clinics delivering hands-on care, representing a healthcare services & facilities business.
|
$129.50M |
$8.45
-0.47%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$126.86M |
$1.09
+2.83%
|
|
SERA
Sera Prognostics, Inc.
Direct Laboratory Testing & Advisory Services provided by SERA for the PreTRM test and related diagnostic offerings.
|
$126.37M |
$3.34
-1.76%
|
|
EHTH
eHealth, Inc.
eHealth's core business is to facilitate enrollment in health insurance products (Medicare and other plans).
|
$124.37M |
$4.08
+2.90%
|
|
IXHL
Incannex Healthcare Limited
Incannex develops oral small-molecule therapeutics as fixed-dose drug combinations (IHL-42X).
|
$124.17M |
$0.34
+1.23%
|
|
IMMX
Immix Biopharma, Inc.
Directly categorizes the company’s lead product as a CAR-T cell therapy (cell therapy).
|
$123.99M |
$4.31
+0.23%
|
|
LNSR
LENSAR, Inc.
Direct ophthalmic device product (Ophthalmology Devices) produced by LENSAR via the ALLY robotic cataract laser system.
|
$123.53M |
$10.35
+3.29%
|
|
USGO
U.S. GoldMining Inc.
Metallurgical testwork and related lab analyses are conducted to inform processing and PEA.
|
$122.90M |
$9.64
+2.66%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$121.23M |
$1.66
+13.36%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$121.01M |
$2.02
+2.27%
|
|
CYBN
Cybin Inc.
Company's pipeline focuses on neuropsychiatric drug development (MDD, GAD) with CYB003/CYB004.
|
$120.61M |
$6.04
-2.11%
|
|
PDEX
Pro-Dex, Inc.
Direct product: the company manufactures surgical instruments (autoclavable, battery-powered multi-function handpieces and shavers).
|
$119.91M |
$36.99
+1.59%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is a recombinant humanized IgG2 monoclonal antibody targeting soluble AßOs.
|
$118.12M |
$1.96
+1.03%
|
|
ARAY
Accuray Incorporated
Accuray's CyberKnife and TomoTherapy/Radixact systems rely on advanced medical imaging for planning and guidance.
|
$117.18M |
$1.05
+4.46%
|
|
BHST
BioHarvest Sciences Inc. Common Stock
BioHarvest operates a CDMO division providing contract development and manufacturing services for plant-based compounds.
|
$116.96M |
$6.92
+1.32%
|
Showing page 24 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
